summary: Methylthioadenosine (MTA) is a natural metabolite with immunomodulatory properties which has been shown to improve the clinical course of an animal model of multiple sclerosis (MS). The authors studied this treatment in a preclinical trial comparing the efficacy with a first line MS treatment and developed an oral formulation. In this preclinical trial, treatment with MTA is more efficacious than first line therapies in an animal model of MS (EAE), with a dose-response effect and higher efficacy when combined with interferon-beta or glatiramer acetate.

authors: Moreno B, Fernandez-Diez B, Di Penta A, Villoslada P.

source: Mult Scler. 2010 Jul 29

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: